A Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult Participants
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT02129088
A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 101
- Registration Number
- NCT02127593
A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2014-06-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT02117505
Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study
Completed
- Conditions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1136
- Registration Number
- NCT02114372
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12024
- Registration Number
- NCT02111564
A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02094378
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 305
- Registration Number
- NCT02087579
A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT02081495
Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 144
- Registration Number
- NCT02079545
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 47
- Registration Number
- NCT02077803
© Copyright 2024. All Rights Reserved by MedPath